We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

8 hedge funds and large institutions have $2.3M invested in Moleculin Biotech in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1,369% more capital inflows, than outflows

Capital inflows: $573K | Capital outflows: $39K

33% more funds holding

Funds holding: 6 → 8 (+2)

1% more ownership

Funds ownership: 3.99% → 4.98% (+1%)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$246K
2
BlackRock
BlackRock
New York
+$81.9K
3
CIBC World Market
CIBC World Market
Ontario, Canada
+$81.9K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$81.9K
5
Northern Trust
Northern Trust
Illinois
+$81.9K

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$24K
2
Wells Fargo
Wells Fargo
California
-$9K
3
Archford Capital Strategies
Archford Capital Strategies
Illinois
-$6K

MBRX Hedge Fund Activity: Q2 2018 in Review

8 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2018, worth a combined $2.3M — up 24% from $1.85M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MBRX positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $246K. The largest seller was Virtu Financial, cutting an estimated $24K.

  • 8 institutional investors held Moleculin Biotech (MBRX) as of Q2 2018, up from 6 in Q1 2018.
  • Funds reported $2.3M of Moleculin Biotech stock for Q2 2018, up 24% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q2 2018 and 0 closed out, a net change of +2 holders.
  • The largest Moleculin Biotech buyer in Q2 2018 was Vanguard Group, an estimated $246K added.
  • The largest Moleculin Biotech seller in Q2 2018 was Virtu Financial, an estimated $24K sold.

Based on aggregated 13F filings for Q2 2018.